JARID2 and hepatocellular carcinoma: Stronger RNA binding ability and weaker DNA binding signal in tumor cells suggest that the canonical methyltransferase functions of EZH2 may be repressed in liver cancer cells, implying their novel regulatory mechanisms of EZH2 and JARID2 in promoting HCC occurrence and development.